Eledon Pharmaceuticals Inc expected to post a loss of 70 cents a share - Earnings Preview

Eledon Pharmaceuticals

20/03/2023 11:06

* Eledon Pharmaceuticals Inc  ELDN.OQ   ELDN.O  is expected
to show no change in quarterly revenue when it reports 
results on March 22 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Eledon
Pharmaceuticals
Inc is for a loss of 70 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Eledon
Pharmaceuticals Inc is $12​, above​ its last closing price
of $2.23. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.68       -0.68      -0.73     Missed  -7.4
 Jun. 30 2022  -0.70       -0.70      -0.65     Beat    7.7
 Mar. 31 2022  -0.67       -0.68      -0.69     Missed  -1.8​
 Dec. 31 2021              -0.75      -0.59     Beat    21.3
 ​​Sep.        -0.63       -0.65      -0.66     Missed  -2.2
 30 2021                                                
 Jun. 30 2021  -0.58       -0.57      -0.50     Beat    11.9​
 Mar. 31 2021  -0.34       -0.32      -0.57     Missed  -78.1
 Dec. 31 2020  -0.31       -1.39      -2.12     Missed  -52
 This summary was machine generated March 20 at 11:06 GMT.  All
figures in US dollars  unless otherwise stated